Within this dataset of tumors harboring POLE mutations (n = 447/14,541), low TMB (TMB-L, <10 mut/Mb) was observed in 39.1% of colorectal cancers (36/92), 30.9% of endometrial cancers (95/307), and 50.0% of ovarian cancers (24/48; Fig. 1A; Table 1). Here, POLE is linked to ovarian carcinoma.